In patients with type 2 diabetes and CVD, the GIP/GLP-1 agonist was as good as the older drug, and possibly better in some ...

SURPASS-CVOT evaluated the efficacy and safety of tirzepatide compared with dulaglutide in adults with T2D and a confirmed ASCVD.

Once-weekly tirzepatide conferred a similar cardiovascular risk as once-weekly dulaglutide in adults with type 2 diabetes and ...

Researchers introduced the PREVENT risk age equations to help determine risk of cardiovascular disease. (JAMA Cardiology) A ...

Topline results from the SURPASS-CVOT trial show that once-weekly tirzepatide has a cardiovascular risk profile similar to ...

Topline results from the SURPASS-CVOT trial reveal that once-weekly tirzepatide (Mounjaro) has a cardiovascular risk profile ...

A recent study shows the use of GLP-1 drugs can increase the risk for optic nerve damage in the first year of treatment, ...

More Chinese adults with type 2 diabetes reduced their HbA1c to below 7% while not gaining weight or experiencing hypoglycemia when assigned dulaglutide vs. glimepiride or insulin glargine ...

From a mean baseline HbA 1c of 8.2%, 0.5 mg semaglutide achieved a statistically significant and superior reduction of 1.5% compared with a reduction of 1.1% with 0.75 mg dulaglutide. People ...

Novo Nordisk’s once-weekly semaglutide has outperformed another weekly therapy, dulaglutide, in controlling blood glucose and helping patients with type 2 diabetes (T2D) lose weight. The drug ...

Dulaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist In AWARD-7, eligible patients (N=577) were randomized to receive dulaglutide 1.5mg once-weekly (N=193), dulaglutide 0 ...

Dulaglutide was FDA approved in 2014 for the treatment of adults with type 2 diabetes. Developer Eli Lilly announced in 2020 that the agent gained an indication to reduce the risk of major adverse ...